Search

Displaying results 2781 - 2790 of 5419 in total
  1. Drug

    Tricaine

    go.drugbank.com/drugs/DB11552
    ExperimentalVet approved

    It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.

  2. Drug

    CGC-11047

    go.drugbank.com/drugs/DB05722
    Investigational

    CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

  3. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. … in position B29 is replaced by proline.

  4. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Clinical studies by the Parkinson's Study Group show that very high doses of an antioxidant called Coenzyme Q (which Mitoquinone effectively targets into mitochondria) appear to slow the progression of

  5. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  6. Drug

    KB3305

    go.drugbank.com/drugs/DB06349
    Experimental

    KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

  7. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    by a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

  8. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use

  9. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    It is an investigational drug under regulatory review by FDA. … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.

  10. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    Allergens containing disulfide bonds are inactivated when reduced by thioredoxin. … It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site.